Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data

Chad Y Lewis; Kunal Mishra; Yuwei Sun; Samantha J Sechrist; Benjamin F Arnold; Nisha R Acharya

doi:10.1016/j.vaccine.2023.04.067

Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data

Vaccine. 2023 May 26;41(23):3493-3496. doi: 10.1016/j.vaccine.2023.04.067. Epub 2023 May 6.

Authors

Chad Y Lewis¹, Kunal Mishra², Yuwei Sun², Samantha J Sechrist², Benjamin F Arnold³, Nisha R Acharya⁴

Affiliations

¹ F.I. Proctor Foundation, University of California, San Francisco, CA, United States; Department of Ophthalmology and Visual Sciences, University of Iowa Hospitals and Clinics, Iowa City, IA, United States.
² F.I. Proctor Foundation, University of California, San Francisco, CA, United States.
³ F.I. Proctor Foundation, University of California, San Francisco, CA, United States; Department of Ophthalmology, University of California, San Francisco, CA, United States.
⁴ F.I. Proctor Foundation, University of California, San Francisco, CA, United States; Department of Ophthalmology, University of California, San Francisco, CA, United States; Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, United States. Electronic address: Nisha.Acharya@ucsf.edu.

Abstract

Recombinant zoster vaccine (RZV) is recommended for individuals ≥ 50 years of age for protection against herpes zoster (HZ). This study quantifies RZV coverage and assesses predictors for RZV vaccination using a U.S. claims database. Univariate linear regression provided annual prevalence of RZV vaccination and multivariable logistic regression provided ORs and 95% CIs for associations between predictors and RZV vaccination. A total of 4,124,315 individuals (19,080,914 person-years) were included in this study. Since receiving FDA approval for the prevention of HZ, RZV coverage (of at least one dose) has reached approximately 17% within the eligible U.S. population by January 2021, although significant disparities between demographic groups were noted. Our findings suggest that HZ vaccine coverage may be reduced below goal in the U.S. and highlights the importance of continuing to monitor RZV vaccination. Additionally, as our study found disparities in vaccine coverage, attention towards marginalized and medically underserved populations is needed.

Keywords: Herpes zoster; Recombinant zoster vaccine; Vaccination coverage.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Cost-Benefit Analysis
Herpes Zoster Vaccine*
Herpes Zoster* / epidemiology
Herpes Zoster* / prevention & control
Herpesvirus 3, Human
Humans
United States
Vaccines, Synthetic

Substances

Herpes Zoster Vaccine
Vaccines, Synthetic

Grants and funding

R01 EY028739/EY/NEI NIH HHS/United States